Surgical adhesive shows promise in bypass
This article was originally published in Clinica
Executive Summary
Researchers in the US have successfully used CryoLife's protein-based surgical adhesive BioGlue to attach vein grafts in experimental bypass surgery performed on goat hearts. The technique could one day be used to re-attach coronary arteries without sutures in minimally-invasive human heart surgery, making the procedure easier and less expensive, says CryoLife president and CEO Steven Anderson.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.